Intraocular drug delivery and filter device and methods of using same

Patent metadata

Field	Value
Publication number	US-10518002-B2
Application number	US-201414916659-A
Country	US
Kind code	B2
Filing date	Sep 8, 2014
Priority date	Sep 6, 2013
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

The present disclosure provides an implantable device comprising a substrate capable of capturing an intraocular target molecule and to methods of use thereof.

First claim

I claim:

1. A method of treating macular degeneration in a subject, the method comprising the steps of:
implanting into an eye of the subject, and in contact with a fluid of the eye, a device comprising polyacrylonitrile fibers;
the polyacrylonitrile fibers having a high affinity for and capturing complement factor D from the fluid;
leaving the device in the eye for a period of time to reduce or alleviate one or more symptoms of macular degeneration; and
regenerating the device in situ by exposing the device to a thermal laser sufficient to denature and release a captured amount of the complement factor D.

2. The method of claim 1 , wherein the polyacrylonitrile fibers substrate comprise a hollow tube.

3. The method of claim 2 , wherein the polyacrylonitrile fibers comprise a plurality of hollow tubes bundled together.

4. The method of claim 1 , wherein the polyacrylonitrile fibers are a solid, a porous matrix, a gel, a sheet, a membrane, a colloid, a microparticle, a nanoparticle, or does not include a polyethylene glycol-conjugated oligonucleotide.

5. The method of claim 1 , wherein the polyacrylonitrile fibers are incorporated into one of a glaucoma drainage device, an aqueous shunting device, an intraocular lens, and a drug delivery device.

6. The method of claim 1 , further comprising the steps of anchoring the device to a tissue of the eye.

7. The method of claim 1 , further comprising the steps of securing the polyacrylonitrile fibers in one of an anterior chamber and a vitreous cavity of the eye.

8. The method of claim 1 , wherein the period of time is at least 6 months.

9. The method of claim 1 , wherein the device has a higher affinity for the complement factor D compared to a corresponding denatured complement factor D.

10. The method of claim 1 , further comprising the step of regenerating the device in situ at least twice.

11. The method of claim 1 , further comprising the step of regenerating the device in situ at least 4 times.

12. The method of claim 1 , wherein the device is coated with an antibody specific to the complement factor D.

13. The method of claim 1 , wherein the polyacrylonitrile fibers are treated with a chemical moiety such that the amount of the complement factor D adsorbed to the surface is visible by color change.

14. A method of treating retinal neovascularization in a subject, the method comprising the steps of:
implanting into an eye of the subject, and in contact with a fluid of the eye, a device comprising hydroxyapatite;
the hydroxyapatite having a high affinity for and capturing vascular endothelial growth factor from the fluid;
leaving the device in the eye for a period of time to reduce or alleviate one or more symptoms of retinal neovascularization; and
regenerating the device in situ by exposing the device to a thermal laser sufficient to denature and release a captured amount of the vascular endothelial growth factor.

15. The method of claim 14 , wherein the hydroxyapatite is a solid, a porous matrix, a gel, a sheet, a membrane, a colloid, a microparticle, a nanoparticle, or does not include a polyethylene glycol-conjugated oligonucleotide.

16. The method of claim 14 , wherein the hydroxyapatite is incorporated into one of a glaucoma drainage device, an aqueous shunting device, an intraocular lens, and a drug delivery device.

17. The method of claim 14 , wherein the period of time is at least 6 months.

18. The method of claim 14 , wherein the device has a higher affinity for the vascular endothelial growth factor compared to a corresponding denatured vascular endothelial growth factor.

19. The method of claim 14 , further comprising the step of regenerating the device in situ at least twice.

20. The method of claim 14 , wherein the hydroxyapatite is treated with a chemical moiety such that the amount of the vascular endothelial growth factor adsorbed to the surface is visible by color change.

Assignees

• Univ Colorado Regents

Inventors

• Olson Jeffrey

Classifications

• A61K9/0051 Primary

  Ocular inserts or implants · CPC title

• A61F9/0017

  implantable in, or in contact with, the eye, e.g. ocular inserts · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L31/146

  Porous materials, e.g. foams or sponges · CPC title

• A61L2300/112

  Phosphorus-containing compounds, e.g. phosphates, phosphonates · CPC title